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Abstract
 
Shp-2, a src homology (SH)2-containing phosphotyrosine phosphatase, appears to be involved
in cytoplasmic signaling downstream of a variety of cell surface receptors, although the mecha-
nism is unclear. Here, we have determined a role of Shp-2 in the cytokine circuit for inflam-
 
matory and immune responses. Production of interleukin (IL)-6 in response to IL-1
 
a
 
 or tumor
 
necrosis factor (TNF)-
 
a 
 
was nearly abolished in homozygous mutant (Shp-2
 
2
 
/
 
2
 
) fibroblast
cells. The targeted Shp-2 mutation has no significant effect on the activation of the three types
of mitogen-activated protein (MAP) kinases, extracellular signal-regulated kinase (Erk), c-Jun
NH
 
2
 
-terminal kinase (Jnk), and p38, by IL-1/TNF, indicating that Shp-2 does not work
through MAP kinase pathways in mediating IL-1/TNF-induced IL-6 synthesis. In contrast,
IL-1/TNF-stimulated nuclear factor (NF)-
 
k
 
B DNA binding activity and inhibitor of 
 
k
 
B (I
 
k
 
B)
phosphorylation was dramatically decreased in Shp-2
 
2
 
/
 
2
 
 cells, while the expression and activ-
ity of NF-
 
k
 
B–inducing kinase (NIK), Akt, and I
 
k
 
B kinase (IKK) were not changed. Reintro-
duction of a wild-type Shp-2 protein into Shp-2
 
2
 
/
 
2
 
 cells rescued NF-
 
k
 
B activation and IL-6
production in response to IL-1/TNF stimulation. Furthermore, Shp-2 tyrosine phosphatase
was detected in complexes with IKK as well as with IL-1 receptor. Thus, this SH2-containing
enzyme is an important cytoplasmic factor required for efficient NF-
 
k
 
B activation. These re-
sults elucidate a novel mechanism of Shp-2 in cytokine signaling by specifically modulating the
NF-
 
k
 
B pathway in a MAP kinase–independent fashion.
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Introduction
 
TNF-
 
a
 
, IL-1
 
a
 
,
 
 
 
IL-1
 
b
 
, and IL-6 are potent immunoregula-
tory and proinflammatory cytokines secreted by a variety of
cell types. These cytokines have similar and broad ranges of
physiological effects in regulating local and systemic im-
mune responses and have also been implicated in several
pathological processes (1, 2). Interestingly, both IL-1 and
TNF are potent inducers of IL-6, which acts to mediate
their biological effects (3). Molecular analysis of the mecha-
nism for IL-6 induction by IL-1 and TNF has often served
as a model system for dissection of cellular events of signal
transduction triggered by these two cytokines.
Two types of IL-1 receptors, type I (IL-1RI) and type II
(IL-1RII), have been identified, and IL-1 appears to trigger
intracellular signaling cascades by binding to IL-1RI, while
IL-1RII may function as a ligand sink (4). The TNF-
 
a
 
 ac-
tivity is elicited by binding to two distinct monomeric
TNF receptors, TNF R-55 and TNF R-75, and most of
the downstream signaling events induced by TNF binding
have been associated with TNF R-55 (5). Neither IL-1 nor
TNF receptor has intrinsic kinase activity and, as such,
their activation signals must be transmitted into cells by ac-
cessory molecules and/or associated cytoplasmic proteins.
The family of TNF receptor–associated factors are involved
in information flow from both TNFR1 and TNFR2 re-
ceptors as well as IL-1 receptor (6). Furthermore, the IL-1
 
receptor–associated serine/threonine kinase (IRAK)
 
1
 
 ap-
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Abbreviations used in this paper: 
 
AP, activator protein; EMSA, electro-
phoretic mobility shift assay; Erk, extracellular signal-regulated kinase;
 
I
 
k
 
B, inhibitor of 
 
k
 
B; IKK, I
 
k
 
B kinase; IRAK, IL-1 receptor–associated
serine/threonine kinase; Jnk, c-Jun NH
 
2
 
-terminal kinase; MAP, mito-
gen-activated protein; MBP, myelin basic protein; NF, nuclear factor;
NIK, NF-
 
k
 
B–inducing kinase; SH, src homology. 
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pears to play a critical role in proximal events of IL-1 re-
ceptor signaling (7, 8).
Induction of IL-6 by IL-1 or TNF seems to involve
multiple cytoplasmic signaling pathways. One prominent
cellular event is the rapid and dramatic activation of nuclear
factor (NF)-
 
k
 
B (9–11). NF-
 
k
 
B is normally inactive and se-
questered in the cytoplasm as a heterodimer comprising
two polypeptides of 50 kD (p50) and 65 kD (p65), which
are noncovalently complexed with a cytoplasmic inhibitory
protein, inhibitor of 
 
k
 
B (I
 
k
 
B). Upon cytokine stimulation,
I
 
k
 
B is rapidly phosphorylated, ubiquitinated, and then de-
graded, resulting in the release and subsequent nuclear
translocation of active NF-
 
k
 
B. NF-
 
k
 
B is critically involved
in transcriptional regulation of the 
 
IL-6
 
 gene, among others
(12, 13). Treatment of cells with IL-1 or TNF also leads to
the activation of three classes of mitogen-activated protein
(MAP) kinases, p42/p44 extracellular signal-regulated ki-
nase (Erk), p54 c-Jun NH
 
2
 
-terminal kinase (Jnk), and p38
MAP kinase, in a variety of cell types (4, 14, 15). Absence
of IRAK expression in targeted mutant fibroblast cells leads
to a defective activation of NF-
 
k
 
B, Jnk, and p38 MAP ki-
nases by IL-1 treatment, which is accompanied by a severe
suppression in IL-1–induced IL-6 production (8). Accu-
mulating biochemical data suggest that both the NF-
 
k
 
B
and the MAP kinase pathways are required for efficient in-
duction of IL-6 by IL-1 or TNF (1, 16). However, it is not
clear whether each of these pathways is distinctly or coor-
dinately controlled in cellular response to cytokines.
Shp-2, a widely expressed cytoplasmic tyrosine phos-
phatase with two src homology (SH)2 domains, has been
implicated in a variety of signal transduction pathways elic-
ited by growth factors, cytokines, hormones, antigens, and
extracellular matrices (17). In previous studies, we created a
Shp-2 mutant mouse model by targeting the exon 3 of the
 
Shp-2
 
 gene (18). Homozygous mutant animals die at mid-
gestation stage with severe defects in the mesodermal pat-
terning, and all of the evidence so far suggests that this is a
loss of function mutation (19–23). Using fibroblast cells de-
rived from Shp-2 mutant embryos, we demonstrated that
Shp-2 is positively involved in mitogenic stimulation of
Erk activity but plays a negative role in the induction of
Jnk activity by cellular stress and also in the IFN-stimulated
Jak/signal transducer and activator of transcription (STAT)
pathway (20, 23).
Here, we present evidence for the first time that a func-
tional Shp-2 molecule is required for IL-6 induction by
IL-1 or TNF. More importantly, we have uncovered a
novel mechanism by which Shp-2 acts to promote IL-6
production via the NF-
 
k
 
B pathway in a MAP kinase–inde-
pendent manner.
 
Materials and Methods
 
Cell Lines and Reagents.
 
Wild-type (Shp-2
 
1
 
/
 
1
 
) and homozy-
gous mutant (Shp-2
 
2
 
/
 
2
 
) embryonic fibroblast cell lines were iso-
lated as described in detail previously (20). Reintroduction of
wild-type Shp-2 protein into Shp-2
 
2
 
/
 
2
 
 fibroblast cells was de-
scribed elsewhere (21). Recombinant mouse TNF-
 
a
 
 was pur-
 
chased from R&D Systems, and recombinant mouse IL-1
 
a
 
 was
provided by Sigma-Aldrich. Antibodies specific for phospho-
Erk1/2, phospho-Jnk, or phospho-p38 MAP kinase were pur-
chased from New England Biolabs, Inc. Polyclonal anti–Shp-2,
antiphosphotyrosine (pY99), anti-TNFR1, anti–IL-1RI, p50, or
p65 of NF-
 
k
 
B antibodies were from Santa Cruz Biotechnology,
Inc. Buffer A is composed of 50 mM 
 
b
 
-glycerophosphate, pH
7.3, 2 mM EDTA, 1 mM EGTA, 5 mM 
 
b
 
-ME, 1% Triton
X-100, and 0.05 M NaCl. Buffer B contains 20 mM HEPES, pH
7.9, 20 mM NaF, 1 mM EDTA, 1 mM EGTA, and 1 mM
dithiothreitol (DTT). Both buffers were also supplemented be-
fore use with 0.2 mM Na
 
3
 
VO
 
4
 
, 0.4 
 
m
 
M microcystin, 0.1 mM
phenylmethylsulfonyl fluoride, 20 
 
m
 
g/ml leupeptin, 1 
 
m
 
M pep-
statin A, and 1 
 
m
 
g/ml aprotinin.
 
Stimulation of Cells and Preparation of Nuclear Extracts.
 
Fibro-
blast cells at 
 
z
 
80% confluency were starved in serum-free
DMEM for 24 h before treatment with IL-1
 
a
 
 or TNF-
 
a
 
. Factor
stimulation was terminated by washing cells with ice-cold PBS,
and cell extracts were made in the following ways. Whole cell
extracts were made by homogenization of cells in Buffer A fol-
lowed by high speed centrifugation. For preparation of nuclear
extracts, pelleted cells were resuspended in three packed cell vol-
umes of Buffer B, swollen for 10 min, and lysed by repeated pas-
sage through a 25-gauge needle. Nuclei were collected by cen-
trifugation at 16,000 
 
g
 
 for 20 min and then extracted in 2.5
packed cell volumes of Buffer B supplemented with 0.42 M
NaCl and 20% glycerol. The supernatant, referred to as the nu-
clear extract, was cleared by centrifugation at 16,000 
 
g
 
 for 30 min
and used for electrophoretic mobility shift assay (EMSA) as de-
scribed below.
 
EMSA.
 
EMSAs were carried out as previously described
(23). The consensus double-stranded oligodeoxynucleotide
probes for NF-
 
k
 
B or for activator protein (AP)-1 (Santa Cruz
Biotechnology, Inc.) were radioactively labeled using 
 
g
 
-[
 
32
 
P]
ATP and T4 polynucleotide kinase using standard procedures.
Nuclear extracts containing 10 
 
m
 
g of total proteins were preincu-
bated with 2 
 
m
 
g of polydI-dC:polydI-dC (Amersham Pharmacia
Biotech) for 20 min in a 20-
 
m
 
l binding reaction mixture (20 mM
HEPES, pH 7.9, 25 mM KCl, 4 mM MgCl
 
2
 
, 0.5 mM DTT,
1 mM EDTA, 10% glycerol), followed by addition of 2 fmol
 
32
 
P-labeled DNA probe and further incubated for 30 min at
room temperature. Resulting protein–DNA complexes were re-
solved on 5% polyacrylamide gels (acrylamide/bisacrylamide 
 
5
 
39:1) containing 2.5% glycerol made in 0.5
 
3 
 
TBE (Tris/borate/
EDTA) buffer. Gels were dried and exposed to X-ray films.
 
In Vitro Erk Kinase Assay.
 
Erk1 kinase was precipitated from
treated or nontreated cell lysates by anti-Erk antibody and protein
A–Sepharose 4B beads (20). The beads were washed twice with
HNTG buffer (20 mM HEPES, pH 7.0, 150 mM NaCl, 0.1%
Triton X-100, 10% glycerol, 1 mM Na
 
3
 
VO
 
4
 
) and once with the
kinase buffer (29 mM HEPES, pH 7.5, 10 mM MgCl
 
2
 
, 2 mM
 
b
 
-ME, 1 mM Na
 
3
 
VO
 
4
 
). The assay was performed by mixing the
beads with 1 mg/ml myelin basic protein (MBP), 80 
 
m
 
M ATP,
and 1.5 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP in the kinase buffer and incubated for
10 min at 30
 
8
 
C. After centrifugation, supernatants were spotted
on p81 Whatman paper, and the papers were washed several
times in 180 mM phosphoric acid and once in 100% ethanol, air
dried, and counted.
 
Immunoprecipitation and Immunoblot Analysis.
 
Cell extracts
were incubated with antibodies prebound to protein A–Seph-
arose beads overnight. The beads were washed three times with
Buffer A with 0.15 M NaCl. For immunoblot analysis, samples
were separated by 10% SDS-PAGE and transferred to a nitrocel- 
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lulose membrane. The membrane was first probed with a specific
antibody and then detected using the ECL system with horserad-
ish peroxidase–conjugated secondary antibodies (Amersham
Pharmacia Biotech).
 
Quantitation of IL-6 Production.
 
For detection of secreted IL-6
protein, cells were first starved in serum-free DMEM for 24 h be-
fore treatment, and then they were treated with IL-1
 
a
 
 or TNF-
 
a
 
for various time periods. Supernatants were collected and ana-
lyzed for IL-6 production using a commercial ELISA kit (R&D
Systems), with recombinant mouse IL-6 as a standard.
 
Northern Blot Analysis.
 
Cells were starved for 24 h and
treated with IL-1
 
a
 
 (10 ng/ml) or TNF-
 
a
 
 (20 ng/ml) for different
time periods. Cells were lysed in guanidinium isothiocyanate
(Kodak) in a Tris-buffered solution and isolated by CsCl density
centrifugation. Total RNA (20 
 
m
 
g) was fractionated through 1%
agarose gel containing 18% formaldehyde and transferred by cap-
illary action to Zeta probe filter for hybridization, using a mouse
IL-6 cDNA fragment (0.6 kb) as a probe (CLONTECH Labora-
tories, Inc.).
 
Results
 
Defective IL-6 Induction by IL-1 or TNF in Shp-2 Mutant
Cells.
 
Both IL-1 and TNF are able to induce a drastic up-
regulation of IL-6 gene expression, and thus assessment of
IL-6 production has been used as a paradigm in dissecting
intracellular signaling pathways elicited by these two cyto-
kines. To determine the possible involvement of Shp-2
tyrosine phosphatase in this process, we first examined
whether IL-6 production is altered in Shp-2
 
2
 
/
 
2
 
 cells under
treatment with IL-1 or TNF. Serum-starved cells were in-
cubated with either IL-1
 
a
 
 or TNF-
 
a
 
 for various time peri-
ods, and supernatants were collected to assay for IL-6 secre-
tion. As shown in Fig. 1 A, IL-6 production induced by
IL-1
 
a
 
 for 4, 8, and 24 h was nearly blocked in Shp-22/2
cells, with a maximal decrease of more than 40-fold as
compared with that in wild-type cells. Similarly, a severe
decrease in the levels of IL-6 secretion was observed in
Shp-22/2 cells after TNF-a treatment (Fig. 1 B). Northern
blot analysis showed much decreased amounts of IL-6
mRNA induced by IL-1/TNF in mutant cells as compared
with that in wild-type cells, pinpointing a problem at the
transcription level (Fig. 1 C). These results indicate the re-
quirement for a functional Shp-2 molecule in mediating
IL-1/TNF-induced cytoplasmic signaling pathways that
culminate in IL-6 induction.
Shp-2 Does Not Mediate IL-6 Induction via the Three MAP
Kinase Pathways. To explore the molecular mechanism
for Shp-2 involvement in mediating IL-6 induction by
IL-1 or TNF, we wanted to examine the activation of
three types of MAP kinases, Erk, Jnk, and p38. It has been
previously reported that IL-1 and TNF activation of one or
more MAP kinases in different cell types has been impli-
cated in IL-6 induction (24, 25). We and others have also
found that Shp-2 is indeed positively required for growth
factor stimulation of Erk activity (20, 26–28).
Erk activity was measured in an in vitro kinase assay with
MBP as a substrate. As shown in Fig. 2, A and B, activation
of Erk by IL-1a or TNF-a was not significantly changed
Figure 1. Suppression of IL-1a/TNF-a–induced IL-6 production in
Shp-22/2 cells. (A and B) Measurement of IL-6 secretion. The establish-
ment of embryonic fibroblast cell lines of wild-type and Shp-2 mutant or-
igins was described in detail previously (20). After starvation in serum-free
DMEM for 24 h, wild-type and Shp-22/2 cells were stimulated with 10
ng/ml IL-1a (A) or 20 ng/ml TNF-a (B) for the indicated times at 378C.
Supernatants were then collected and measured for IL-6 secretion using a
commercial ELISA kit (R&D Systems), with recombinant mouse IL-6 as
a standard. Data shown are the means of three independent experiments 6
SD. (C). Northern blot analysis of IL-6 transcript. Total RNA was ex-
tracted from control and factor-treated cells, and Northern blotting was
performed using a specific IL-6 cDNA probe. The membrane was
stripped and reprobed with a cDNA fragment of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) as an internal control.104 A New Function of Shp-2 in the NF-kB Pathway
in Shp-22/2 cells, as compared with that in wild-type cells.
To extend this observation, we examined extensively the
activities of all three major members of the MAP kinase
family, Erk, Jnk, and p38, using antibodies specific for
phosphorylated forms of p44/42 Erk1/2, p54/56 Jnk, and
p38 (Fig. 2, C and D). Consistent with previous observa-
tions (25), we found that stimulation of cells by IL-1a– or
TNF-a–activated Jnk and p38 MAP kinases more promi-
nently than Erk in fibroblast cells. Interestingly, in contrast
to the dramatic inhibition of IL-6 induction, activation of
all three types of MAP kinases was either not changed or
even slightly higher in Shp-22/2 than in wild-type cells in
response to IL-1/TNF stimulation.
Downstream of MAP kinases, AP-1 can be activated di-
rectly through phosphorylation by Jnk, and the expression
of AP-1 components is induced through Jnk- and p38-
dependent activation of transcription factors. To assess the
effect of Shp-2 on IL-1–induced AP-1 activation, we mea-
sured AP-1 activity by EMSA assay, by incubating a
radiolabeled oligonucleotide probe for the AP-1 binding
site with nuclear extracts prepared from untreated and IL-
1a–treated cells. Consistent with the results for the activa-
tion of MAP kinases, treatment with IL-1a resulted in a
similar increase in the levels of AP-1 DNA binding in
wild-type and Shp-22/2 cells (Fig. 3), and similar results
were obtained after TNF-a stimulation (data not shown).
NF-kB Activation Is Severely Attenuated in Shp-22/2
Cells. The results described above indicate that the defec-
tive IL-6 induction in Shp-2 mutant cells is not due to
downregulation of one or more MAP kinase activities, and
it is unlikely that Shp-2 mediates cellular responses to IL-1/
TNF via manipulating the MAP kinase pathways. This ob-
servation prompted us to search for other signaling routes
that are influenced by Shp-2. As IL-1a and TNF-a are the
two most efficient activators of NF-kB, we monitored the
NF-kB activation by IL-1a or TNF-a in wild-type and
Shp-22/2 fibroblasts by measuring DNA binding activity of
NF-kB in nuclear extracts with a NF-kB–specific oligonu-
cleotide probe. Treatment of wild-type fibroblast cells by
IL-1a or TNF-a for 15, 30, and 60 min resulted in a dra-
matic induction of DNA binding activity of NF-kB (Fig.
4, A and B). However, compared with the induction in
wild-type cells, NF-kB activation was significantly dimin-
ished in Shp-22/2 cells after treatment with either IL-1a or
TNF-a. This is in contrast to the similar induction of AP-1
activity as well as MAP kinase activities in wild-type and
Figure 2. Normal activation of MAP kinases by
IL-1a/TNF-a. (A and B) Serum-starved wild-type
and Shp-22/2 cells were treated with 10 ng/ml IL-
1a (A) or 20 ng/ml TNF-a (B) for the indicated
time periods. ERK1 was immunoprecipitated for
an in vitro kinase assay using MBP as a substrate as
previously described (20). (C and D) Whole cell
extracts were prepared from control and factor-
treated cells. Equal amounts of cell lysates (40 mg of
total proteins) were subjected to immunoblot anal-
ysis with anti–phospho-ERK-42/44, anti–ERK-
42/44, anti–phospho-p46/54 Jnk, anti-p46/54 Jnk,
anti–phospho-p38, and anti-p38 MAPK antibodies.
Figure 3. AP-1 activation by IL-1. Serum-starved wild-type and Shp-
22/2 cells were treated with 10 ng/ml IL-1a for the indicated time peri-
ods. Nuclear extracts were prepared for detection of AP-1 activity using
EMSA with radiolabeled probe containing the consensus AP-1 binding
site (59-CGC TTG ATG AGT CAG CCG GAA-39; obtained from
Promega). The arrow denotes the specific AP-1–DNA complexes.105 You et al.
Shp-22/2 cells as described above. Thus, Shp-2 appears to
modulate IL-1a/TNF-a signaling by specifically modulat-
ing NF-kB activation rather than the MAP kinase–AP-1
pathway.
Mechanism for Shp-2 Function in the NF-kB Pathway.
Our results point to a new function of Shp-2 in cytoplas-
mic signaling initiated by cytokines. To further dissect the
mechanism for Shp-2 function in mediating NF-kB activa-
tion, we examined the phosphorylation status of IkB. The
NF-kB protein is sequestered in the cytoplasm as an inac-
tive complex with the inhibitor IkB, and cytokine-induced
IkB phosphorylation is required for IkB degradation and
consequent NF-kB activation. Cells were treated with ei-
ther IL-1a or TNF-a for 1, 2, 3, 5, and 8 min, and cell ly-
sates were immunoblotted with antibodies specific for
phospho-IkB and IkB, respectively (Fig. 5). Stimulation
with IL-1a or TNF-a induced a robust increase in the
phosphorylation levels of IkB in wild-type cells. In con-
trast, only mild levels of IkB phosphorylation were ob-
served in Shp-22/2 cells after IL-1/TNF treatment. This
result confirmed that the defective NF-kB activation is
caused by a severe reduction in the IkB phosphorylation in
Shp-22/2 cells.
We then evaluated the expression and activities of sev-
eral upstream kinases that are involved in IkB phosphoryla-
tion, including IkB kinase (IKK), NF-kB–inducing kinase
(NIK), and Akt/protein kinase B. As detected by immuno-
blot analysis, the protein amounts for IKKs, NIK, and Akt
were not changed in Shp-22/2 cells (Fig. 6). The activity of
immunoprecipitated IKKa, the kinase that phosphorylates
IkBa directly, was measured using purified IkBa (amino
acids 1–317) as a substrate in vitro. There was no significant
difference observed for IKKa activity in vitro between
wild-type and Shp-22/2 cells after IL-1/TNF treatment
(Fig. 6 A), and similar results were obtained for IKKb (Fig.
6 B). As shown in Fig. 6 C, we detected similar levels of
Akt kinase activity, and Akt was possibly involved in pro-
moting the NF-kB pathway by activating IKK (29–31).
Taken together, our results indicate that the activity of
IKK, and thus the activation of upstream kinases Akt and
NIK, was not altered when tested in an in vitro assay. We
then searched for physical evidence for the Shp-2 involve-
ment in the NF-kB pathway by co-immunoprecipitation
Figure 4. Reduced NF-kB activity in
Shp-22/2 cells in response to IL-1a/
TNF-a stimulation. Nuclear extracts
were prepared from control and factor-
stimulated cells, and NF-kB DNA bind-
ing activity was measured by EMSA
with a radiolabeled probe containing the
consensus NF-kB binding site (59-AGT
TGA GGG GAC TTT CCC AGG
C-39; from Santa Cruz Biotechnology,
Inc.). Arrows denote the specific NF-
kB–DNA complexes. In supershift as-
says (SS) in A and B, antibodies against
the p50 or p65 subunit of NF-kB were
added to the reaction mixture before in-
cubation with the DNA probe.
Figure 5. Diminished IkB phosphorylation in Shp-22/2 cells. Serum-
starved cells were stimulated with either IL-1a (A) or TNF-a (B) for 1, 2,
3, 5, and 8 min, and the cell lysates were prepared for immunoblot analy-
sis with either an anti–phospho-IkBa (anti–P-IkBa) or an anti-IkBa an-
tibody. In parallel, the same samples were also blotted with anti-Erk anti-
body for loading control.106 A New Function of Shp-2 in the NF-kB Pathway
and found that Shp-2 was constitutively associated with
IKKa, which was not influenced by IL-1/TNF treatment
(Fig. 6, E and F). Therefore, Shp-2 is physically involved in
a multimeric protein complex that is required for efficient
phosphorylation of IkB and hence the activation of NF-kB
in vivo.
To explore further the involvement of Shp-2 in IL-1
signaling, we investigated the physical interaction of Shp-2
with IL-1RI. Shp-2 was precipitated from cell lysates, and
the resultant immunoprecipitates were subjected to immu-
noblot analysis with an anti–IL-1RI antibody. As shown in
Fig. 7, Shp-2 was found in association with IL-1RI, and
the complex was detected irrespective of ligand stimula-
tion. Participation of Shp-2 in the IL-1RI complex was
further confirmed in converse experiments in which the
anti–IL-1RI immune complex was also found to contain
Shp-2. In parallel experiments, we did not observe the
physical association of Shp-2 with the TNF-a receptor
(data not shown).
Rescue of the Mutant Phenotype by Reintroduction of Wild-
Type Shp-2. To confirm that the defect in IL-1/TNF-
induced NF-kB activation and IL-6 production were
caused by absence of a functional Shp-2, we reevaluated
cellular responses to the cytokine stimulation in Shp-22/2
cells in which a wild-type Shp-2 was reintroduced. As il-
lustrated in Fig. 8, reintroduction of wild-type Shp-2 pro-
Figure 6. Expression and activity of compo-
nents in the NF-kB pathway. (A and B) In
vitro kinase activity assay for IKKa and IKKb.
The IKKa and -b kinases were immunoprecip-
itated, using their specific antibodies from con-
trol and factor-treated cell lysates and assayed
for activity using purified glutathione-S-trans-
ferase fusion protein containing the NH2-ter-
minal part of IkBa (amino acids 1–317) as a
substrate. The protein amount of the kinase in
each sample was determined by immunoblot
analysis with anti-IKKa (BD PharMingen) and
anti-IKKb (Santa Cruz Biotechnology, Inc.)
antibodies, respectively. (C) Akt activation by
IL-1a and TNF-a was analysed by immuno-
blotting with anti–P-Akt antibody (New En-
gland Biolabs, Inc.), and its protein amount was
visualized by anti-Akt blotting. (D) The expres-
sion levels of NIK in wild-type and mutant cells
were determined by anti-NIK immunoblotting.
(E and F) Control and IL-1a/TNF-a–treated
cell lysates were precipitated with anti-IKKa
antibody, and the precipitates were blotted with
either anti–Shp-2 or anti–IKKa antibodies.
Bands for the wild-type and Shp-2D proteins are
indicated.
Figure 7. Interaction of Shp-2 with IL-1RI.
Serum-starved wild-type and Shp-22/2 cells
were treated with 10 ng/ml IL-1a for the indi-
cated time periods. (A) Whole cell extracts
were immunoprecipitated with anti–Shp-2 an-
tibody or preimmune antiserum (Pre.). The re-
sulting immunoprecipitates were resolved on
SDS–polyacrylamide gel and immunoblotted
with anti-IL-1RI or anti–Shp-2 antibodies as
indicated. (B) Cell lysates were immunoprecipi-
tated with anti–IL-1RI antibody and subjected
to immunoblot analysis with anti–Shp-2 or
anti–IL-1RI antibodies. Bands for the wild-
type and Shp-2D proteins are indicated.107 You et al.
tein rescued the activation of NF-kB by IL-1a or TNF-a.
Furthermore, expression of wild-type Shp-2 in mutant cells
resulted in a significant increase of IL-6 secretion (Fig. 8).
Collectively, these results revealed a new function for
the cytoplasmic phosphotyrosine phosphatase, Shp-2, in
mediating the induction of NF-kB activity and IL-6 syn-
thesis by IL-1a and TNF-a in inflammatory and immune
responses.
Discussion
In this study, we identified an important role of Shp-2 in
a cytokine network by mediating the IL-6 induction by IL-
1/TNF. It is well known that IL-6 acts to mediate and am-
plify the biological activities of IL-1 and TNF in a number
of physiological and pathological processes (1). However,
the molecular mechanism for the induction of IL-6 by IL-
1/TNF is not fully understood. Previous studies suggest
that activation of two signaling pathways, NF-kB and
MAP kinases, is required for efficient induction of IL-6 by
the two cytokines (4, 16). In exploring the molecular
mechanism by which Shp-2 mediates the cytokine circuit,
we first examined the Erk kinase activity, as our previous
results indicate that Erk kinase activation is either severely
diminished or even blocked in Shp-22/2 cells upon various
growth factor stimulation (20). Surprisingly, IL-1/TNF-
induced Erk activity was not significantly altered in a com-
parison between wild-type and Shp-22/2 cells. We then as-
sessed the activities of the other two MAP kinases, Jnk and
p38, upon stimulation of IL-1/TNF. Consistent with the
literature (25), our results demonstrate that induction of
these two types of MAP kinases are more profound than
Erk in cellular responses to IL-1/TNF. However, there
was no significant difference in IL-1/TNF-induced Jnk and
p38 activities between wild-type and mutant cells. Thus, it
is unlikely that Shp-2 acts through MAP kinase pathways
to mediate the IL-6 induction by IL-1/TNF. Having ob-
tained these results, we shifted our attention to the NF-kB
pathway. Data from subsequent experiments indicate that
Shp-2 indeed plays a critical role in positive regulation of
IL-1/TNF-induced NF-kB activity that leads to IL-6 pro-
duction, a previously unidentified mechanism for Shp-2
function in cell signaling.
NF-kB is a master transcription factor involved in the
control of inflammatory response elicited by IL-1 and
TNF. Previous studies suggest that stimulation of a kinase
cascade by proinflammatory cytokines leads to the activa-
tion of the IKK complex that directly phosphorylates IkB
(32). Now, our results indicate that Shp-2 is also an integral
component of the IKK complex, and a functional Shp-2 is
required for efficient phosphorylation of IkB by the IKK
complex in cellular response to IL-1/TNF. This finding
Figure 8. Rescue of the mutant phenotype
by reintroduction of wild-type Shp-2. Shp-22/2
cells were transfected with a pcDNA3.1 vector
or a wild-type Shp-2 cDNA expression con-
struct, and clones expressing wild-type Shp-2
were isolated (reference 21). Shp-22/2 cell lines
transfected with the vector only (V) or express-
ing wild-type Shp-2 (R4) were treated with 10
ng/ml IL-1a or 20 ng/ml TNF-a for the indi-
cated time periods. (A and B) The amounts of
secreted IL-6 in supernatants were determined by ELISA as described in Fig. 1. Data shown are the
means of three independent experiments 6 SD. (C) Nuclear extracts were prepared for detection of
NF-kB activity as described in Fig. 4. The arrows denote the specific NF-kB–DNA complexes. (D)
IkBa phosphorylation was evaluated by anti–P-IkBa antibody blotting.108 A New Function of Shp-2 in the NF-kB Pathway
might be instrumental for designing a novel therapeutic
strategy for inflammatory and immune disorders by specifi-
cally manipulating Shp-2 activity in vivo. The positive ef-
fect of Shp-2 on activation of NF-kB, combined with our
previously identified negative regulatory role of Shp-2 in
interferon-stimulated Jak/STAT pathway (20, 23), may
constitute a protective mechanism of cells against apoptosis.
We and others have described a complicated role of
Shp-2 in MAP kinase cascades (20, 26–28). This phos-
phatase acts to promote mitogenic stimulation of Erk activ-
ity while being a negative regulator in the activation of Jnk
by cellular stress (20). The most interesting part of this re-
port is that, although all three types of MAP kinases are ac-
tivated to variable extents by IL-1/TNF, Shp-2 is appar-
ently not involved in any of the processes. In aggregate,
these observations suggest that Shp-2 is engaged in multiple
cytoplasmic pathways by different mechanisms, possibly
due to subcellular targeting of the enzyme to different sub-
strates. In mediating Erk induction by epidermal growth
factor, Shp-2 is recruited into an oligomeric protein com-
plex assembled on Gab1 scaffolding molecule and appears
to dephosphorylate an unidentified phosphoprotein, p90,
in promoting the Ras–Erk pathway (33). Results in this re-
port show that Shp-2 participates in signaling complexes
assembled around IL-1 receptor as well as IKK.
As reported previously (18–20), a mutant Shp-2 protein
(Shp-2D) lacking 65 amino acids in the SH2-N domain was
expressed in the targeted mutant cells due to aberrant splic-
ing. In epidermal growth factor (EGF)-treated cells, ty-
rosine-phosphorylated Gab1 selectively associates with the
wild-type but not the mutant Shp-2 molecule, correlating
with a defect in EGF-stimulated Erk activation (33). How-
ever, Shp-2 appears to be constitutively associated with
IKK and IL-1RI, and the mutant Shp-2D molecule was also
detected in these complexes. This is similar to what we de-
scribed for the interaction of Shp-2 with IFN-a and -g re-
ceptors (23). At this moment, the molecular basis for Shp-2
activity in the NF-kB pathway is not yet fully understood.
Although this is a typical tyrosine phosphatase from its mo-
lecular architecture, we have not excluded the possibility
that Shp-2 may act as a dual-specificity phosphatase. It is
also possible that Shp-2 functions as an adapter molecule in
mediating the activation of NF-kB, and an intact SH2-N
domain is possibly required for recruitment of other signal-
ing components into the IL-1RI and IKK complexes.
Shp-2D is clearly a loss-of-function molecule, as the defects
in IL-1/TNF signaling in mutant cells were rescued by re-
introduction of wild-type Shp-2.
Kanakaraj et al. reported recently (8) that in IRAK-defi-
cient fibroblast cells, IL-1–induced Jnk, p38, and NF-kB
activities were all decreased, accompanied by a dramatic re-
duction in IL-6 secretion. At high concentrations, IL-1 in-
duced a normal NF-kB response but not the response of
Jnk and p38 in IRAK-deficient cells. But even under this
condition, IL-6 induction by IL-1 was significantly lower
in mutant than in wild-type cells, suggesting that efficient
activation of IL-6 gene expression requires two signals, de-
livered by NF-kB and MAP kinases. Consistently, another
recent report by Vanden Berghe et al. (34) suggests a co-
operation between NF-kB and MAP kinases for TNF-
induced IL-6 gene expression in that Erk and p38 modu-
late the transactivation potential of NF-kB without affecting
its DNA binding activity.
Defects in both the NF-kB and MAP kinase pathways in
IRAK-deficient cells suggest an involvement of IRAK in a
proximal common event downstream of IL-1 receptor that
signals activation of both pathways. In this regard, it is in-
teresting to note that, although Shp-2 apparently operates
in signal relay proximally from IL-1 receptor complex, it
has a specific effect on the NF-kB pathway only, without
influencing the MAP kinase cascades. Therefore, pharma-
ceutical interference of this specific activity of Shp-2 in cell
signaling might be clinically useful for the treatment of IL-
1–mediated inflammatory diseases without side-effects.
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